Correction: PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer(PLoS ONE (2019)8:1(e53292) Doi:10.1371/journal.pone.0053292);PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Loi, Sherene ^a   Michiels, Stefan ^a   Baselga, Jose ^b   Bartlett, John M S ^c,d   Singhal, Sandeep K ^a   Sabine, Vicky S ^c   Sims, Andrew H ^c   Sahmoud, Tarek ^e   Dixon, J Michael ^c   Piccart, Martine J ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; EVEROLIMUS; KI 67 ANTIGEN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN S6;

AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84871820669     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0216175     Document Type: Erratum

References (23)

1. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
2. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, et al. (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106: 22299-22304.
3. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, et al. (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16: 3670-3683.
4. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, et al. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.
5. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, et al. (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11: 5319-5328.
6. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, et al. (2012) Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 366: 520-529.
7. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, et al. (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107: 10208-10213.
8. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, et al. (2010) Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119: 379-390.
9. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, et al. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059.
10. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, et al. (2012) PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14: R28.
11. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
12. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2006) Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 12: 1024s-1030s.
13. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, et al. (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100: 1380-1388.
14. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, et al. (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637.
15. Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, et al. (2010) The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat.
16. Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, et al. (2010) Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 122: 419-428.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
18. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
19. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, et al. (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3: e3065.
20. Whyte DB, Holbeck SL, (2006) Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 340: 469-475.
21. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, et al. (2010) Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 12: R76.
22. Chow LWC, Sun YA, Jassem J, Baselga J, Hayes DF,et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer; 2006; San Antonio, TX. Breast Cancer Res Treat 2006(suppl 1): 6091.
23. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, et al. (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30: 2718-2724.